These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 23864239)
1. Predominantly proinflammatory cytokines decrease after B cell depletion therapy in patients with primary Sjogren's syndrome. Pollard RP; Abdulahad WH; Bootsma H; Meiners PM; Spijkervet FK; Huitema MG; Burgerhof JG; Vissink A; Kroese FG Ann Rheum Dis; 2013 Dec; 72(12):2048-50. PubMed ID: 23864239 [No Abstract] [Full Text] [Related]
2. Complete remission of protein-losing gastroenteropathy associated with Sjögren's syndrome by B cell-targeted therapy with rituximab. Uraoka Y; Tanigawa T; Watanabe K; Machida H; Okazaki H; Yamagami H; Watanabe K; Tominaga K; Watanabe T; Fujiwara Y; Arakawa T Am J Gastroenterol; 2012 Aug; 107(8):1266-8. PubMed ID: 22859008 [No Abstract] [Full Text] [Related]
3. Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sjögren's syndrome after B cell depletion therapy. Hamza N; Bootsma H; Yuvaraj S; Spijkervet FK; Haacke EA; Pollard RP; Visser A; Vissink A; Kallenberg CG; Kroese FG; Bos NA Ann Rheum Dis; 2012 Nov; 71(11):1881-7. PubMed ID: 22615459 [TBL] [Abstract][Full Text] [Related]
4. [B-cell depletion and primary Sjögren's syndrome: is there a role for rituximab?]. Atzeni F; Sarzi-Puttini P Reumatismo; 2010; 62(2):87-8. PubMed ID: 20657883 [No Abstract] [Full Text] [Related]
6. Does rituximab help patients with primary Sjögren syndrome? Ann Intern Med; 2014 Feb; 160(4):I-11. PubMed ID: 24727838 [No Abstract] [Full Text] [Related]
7. EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial. Moerman RV; Arends S; Meiners PM; Brouwer E; Spijkervet FK; Kroese FG; Vissink A; Bootsma H Ann Rheum Dis; 2014 Feb; 73(2):472-4. PubMed ID: 23940214 [No Abstract] [Full Text] [Related]
8. Rituximab modulates the expression of IL-22 in the salivary glands of patients with primary Sjogren's syndrome. Ciccia F; Giardina A; Rizzo A; Guggino G; Cipriani P; Carubbi F; Giacomelli R; Triolo G Ann Rheum Dis; 2013 May; 72(5):782-3. PubMed ID: 23264342 [No Abstract] [Full Text] [Related]
9. Immune regulation and B-cell depletion therapy in patients with primary Sjögren's syndrome. Abdulahad WH; Kroese FG; Vissink A; Bootsma H J Autoimmun; 2012 Aug; 39(1-2):103-11. PubMed ID: 22341852 [TBL] [Abstract][Full Text] [Related]
10. First report of improvement of coeliac disease in a patient with Sjögren's syndrome treated with rituximab. Nikiphorou E; Hall FC Rheumatology (Oxford); 2014 Oct; 53(10):1906-7. PubMed ID: 24729401 [No Abstract] [Full Text] [Related]
11. Summaries for patients. Does rituximab help patients with primary Sjögren syndrome? Ann Intern Med; 2014 Feb; 160(4):I-11. PubMed ID: 25006621 [No Abstract] [Full Text] [Related]
12. Treatment of primary Sjögren syndrome with rituximab. Faustman DL; Vivino FB; Carsons SE Ann Intern Med; 2014 Sep; 161(5):376-7. PubMed ID: 25178574 [No Abstract] [Full Text] [Related]
13. Treatment of primary Sjögren syndrome with rituximab. In response. Saraux A; Nowak E; Devauchelle-Pensec V Ann Intern Med; 2014 Sep; 161(5):377-8. PubMed ID: 25178575 [No Abstract] [Full Text] [Related]